Rob Kaplan, Goldman Sachs vice chair and former Dallas Fed president, argues that senior executives face a critical, often overlooked danger: the absence of oversight from above, which can lead to isolation, blind spots, and derailment.
In a keynote address, Goldman Sachs Vice Chairman Robert Steven Kaplan dissected the potent mix of challenges and catalysts shaping the U.S. economic outlook, from persistent trade policies to the transformative potential of artificial intelligence.
Longleaf Partners' Q4 2025 letter highlights Graham Holdings as a standout, crediting its diversified portfolio and the successful restructuring of its Kaplan education unit for steady performance in a turbulent small-cap environment.
The multi-billion dollar college test preparation industry is undergoing a seismic shift as advanced AI chatbots offer personalized tutoring for free. While established companies like Kaplan and The Princeton Review are integrating AI into their services, the rise of accessible tools like Google's Gemini is forcing a fundamental rethink of value and cost.
Despite a mixed financial performance in 2025, Douglas Emmett reports a significant quarter of positive office space absorption in its core Los Angeles markets and strong multifamily results. The REIT outlines a strategic focus on high-end residential development and opportunistic office acquisitions for the coming year, while managing a cautious outlook on interest expenses.
Sol Strategies Inc. (STKE) reported a 69% year-over-year surge in staking income for Q1 2026, driven by its new liquid staking token and validator expansion, while outlining an aggressive M&A strategy to solidify its position in the Solana ecosystem.
Newly released U.S. Justice Department documents reveal Morgan Stanley opened and managed accounts for Jeffrey Epstein's trusts as late as 2019, long after his 2008 conviction, highlighting ongoing questions about Wall Street's due diligence with high-risk clients.
Financial advisors highlight critical, yet often missed, tax strategies for retirees—from Roth conversions to charitable giving—that can preserve wealth and prevent costly regrets on a fixed income.
Despite a net income dip, Corcept Therapeutics reported robust Q4 revenue growth and issued confident 2026 guidance, fueled by its Cushing's syndrome business and anticipation for its ovarian cancer drug Relicorant, even as it contends with FDA pushback and a major generic transition.
San Francisco Fed President Mary Daly expressed confidence that current monetary policy settings are appropriate, citing an improved labor market and expectations for inflation to resume its downward trend as tariff impacts fade.
Sabra Health Care REIT (SBRA) has seen its shares climb steadily over recent months, catching the eye of investors revisiting the healthcare real estate sector. With a one-year total shareholder return exceeding 30%, we examine whether the current price still presents a value opportunity or if future growth is already priced in.
Aptiv's latest quarterly results and 2026 outlook, paired with accelerated share repurchases, have drawn investor scrutiny. While recent momentum is positive, long-term performance and a premium valuation raise questions about the stock's runway in a shifting automotive landscape.
Citigroup nudges its price target for insurance broker Arthur J. Gallagher higher, while UBS trims its own but maintains a constructive long-term view on the sector, as the company bolsters its retirement services with a new acquisition.
President Trump's laissez-faire stance on the dollar's slide to a four-year low risks backfiring on his core promise to lower living costs, as analysts warn a weak currency could fuel inflation and thwart rate cuts.
